Lohmann Animal Health has signed long-term cooperation contracts with Taiwan research institutes in order to expand its global business activities and compound product portfolio on an international scale. These agreements include the foundation of a new subsidiary, Lohmann Animal Health Pingtung, and the planned building of a GMP facility for vaccine production in the Pingtung Agricultural Biotechnology Park, according to the company.
"With this signing we lay the foundation for future collaboration with the Animal Health Research Institute, the Animal Technology Institute Taiwan and other research institutes and universities," said Dr. Bruno Kaesler, managing director of Lohmann. "With the high level of know-how and the focused result orientation of the scientists here, as Lohmann Animal Health we are committed to converting those research products into commercial success as we are convinced the range of new vaccines in development and the innovative technology involved, represent a great market potential."
In phase I of three phases already planned for the collaboration with the institutes, Lohmann will establish its new subsidiary Lohmann Animal Health Pingtung and start the building of a technical center according to European GMP standards, including a modular animal house. The facility will arise in Pingtung Agricultural Biotechnology Park and will primarily serve for long-term process development, provision for formulations of first quantities up to large-scale production for those products currently in the final development phase. The Lohmann Pingtung Agricultural Biotechnology Park facility will be an important platform for the results of biological research to become successful products of commercial value, both for Taiwan and internationally.
"Progress is a step-by-step process, and we are optimistic and determined to meet the ambitious expectations of our partners and the Taiwanese government," said Kaesler. "We believe this investment to be a win-win project for both Taiwan and Lohmann Animal Health on a long-term basis and beneficial for Taiwanese biotechnology - today and tomorrow."
"With this signing we lay the foundation for future collaboration with the Animal Health Research Institute, the Animal Technology Institute Taiwan and other research institutes and universities," said Dr. Bruno Kaesler, managing director of Lohmann. "With the high level of know-how and the focused result orientation of the scientists here, as Lohmann Animal Health we are committed to converting those research products into commercial success as we are convinced the range of new vaccines in development and the innovative technology involved, represent a great market potential."
In phase I of three phases already planned for the collaboration with the institutes, Lohmann will establish its new subsidiary Lohmann Animal Health Pingtung and start the building of a technical center according to European GMP standards, including a modular animal house. The facility will arise in Pingtung Agricultural Biotechnology Park and will primarily serve for long-term process development, provision for formulations of first quantities up to large-scale production for those products currently in the final development phase. The Lohmann Pingtung Agricultural Biotechnology Park facility will be an important platform for the results of biological research to become successful products of commercial value, both for Taiwan and internationally.
"Progress is a step-by-step process, and we are optimistic and determined to meet the ambitious expectations of our partners and the Taiwanese government," said Kaesler. "We believe this investment to be a win-win project for both Taiwan and Lohmann Animal Health on a long-term basis and beneficial for Taiwanese biotechnology - today and tomorrow."
No comments:
Post a Comment